We are currently looking for patients with the following conditions:

  • Venous Leg Ulcers (VLUs)
  • Diabetic Foot Ulcers (DFUs)
  • Achilles Tendonitis
  • Plantar Fasciitis
  • Bunions

If you are interested in learning more, please contact us here www.lppresearch.com.


Published Research Articles

Feasibility and Efficacy of a Smart Mat Technology to Predict Development of Diabetic Plantar Ulcers
http://care.diabetesjournals.org/content/40/7/973

Baseline factors affecting closure of venous leg ulcers
https://www.sciencedirect.com/science/article/pii/S2213333X17303517

Phase 3 evaluation of HP802-247 in the treatment of chronic venous leg ulcers
http://onlinelibrary.wiley.com/doi/10.1111/wrr.12467/abstract

Evaluation of tissue engineering products for the management of neuropathic diabetic foot ulcers: an interim analysis
http://www.magonlinelibrary.com/doi/abs/10.12968/jowc.2016.25.Sup7.S18

Healing Rates in a Multicenter Assessment of a Sterile, Room Temperature, Acellular Dermal Matrix Versus Conventional Care Wound Management and an Active Comparator in the Treatment of Full-Thickness Diabetic Foot Ulcers
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750365/

The Management of Diabetic Foot Ulcers with Porcine Small Intestine Submucosa Tri-Layer Matrix: A Randomized Controlled Trial
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651054/

Central talar dome lesions: a unique surgical approach with incorporation of a talar allograft for joint reconstitution and restoration of function
https://www.ncbi.nlm.nih.gov/pubmed/21406705

A multicentre randomised controlled trial evaluating the efficacy of dehydrated human amnion/chorion membrane (EpiFix®) allograft for the treatment of venous leg ulcers
http://onlinelibrary.wiley.com/doi/10.1111/iwj.12843/full

A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator
http://onlinelibrary.wiley.com/doi/10.1111/wrr.12551/full


Clinical Research Trials

Principal Investigator for the following trials:

A phase 3 randomized, placebo-controlled, blinded study to investigate the safety and efficacy of a topical gentamicin-collagen sponge in combination with systemic antibiotic therapy in diabetic patients with an infected foot ulcer

A phase IIb, prospective, single-blinded, randomized controlled trial of the micronized dHACM injection as compared to the saline placebo injection in the treatment of plantar fasciitis

A multicenter prospective, randomized, controlled, comparative parallel study of dehydrated human amnion/chorion membrane (dHACM) wound graft in the management of diabetic foot ulcers

A phase-3 prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and efficacy of Curexcell® as an adjunct to good ulcer care measures in treating chronic venous leg ulcers

A multicenter, randomized, controlled, open-label trial to assess the clinical effectiveness of DermACELL®, conventional care wound management, and Graftjacket® in subjects with chronic wounds in the lower extremities

An evaluation of tissue engineering approaches for treatment of neuropathic diabetic foot ulcers resistant to standard of care: a prospective, randomized controlled trial

A phase III, multinational, multicenter, randomized, double-blind, parallel-group, sham-controlled study to evaluate the safety, tolerability and efficacy of Curexcell® as an adjunct to good wound care measures in treating lower extremity chronic ulcers in adults with diabetes mellitus

A phase 3 randomized, double blind, vehicle controlled study investigating the safety and efficacy of HP802-247 in the treatment of venous leg ulcers >12 cm2 to ≤ 36 cm2

A phase 3 randomized, double blind, vehicle controlled study investigating the safety and efficacy of HP802-247 in the treatment of venous leg ulcers

A non-interventional safety study providing 12 months follow-up from first exposure to HP802-247 in subjects with venous leg ulcer

A multi-center, randomized, controlled clinical trial to evaluate the safety and effectiveness of Integra® dermal regeneration template for the treatment of neuropathic diabetic foot ulcers

In-Balance VLU inflammation, bacteria, & angiogenesis effects in launching venous leg ulcer healing

Restoring equilibrium and wound stimulation to promote healing of non-healing DFUs

A phase II, randomized, controlled, multi-center study of the safety and efficacy of topically applied Mebo® wound ointment compared to standard of care in subjects with diabetic foot ulcers

Clinical outcomes associated with enzymatic debridement of diabetic foot ulcers for up to 12 weeks with clostridial collagenase (Santyl®) ointment

A phase 2 multicenter, randomized, double-blind, placebo–controlled, dose range finding study to evaluate the efficacy and safety of intramuscular injection of human placenta-derived cells (PDA-002) in subjects who have diabetic foot ulcer with peripheral arterial disease

Epifix® vs. standard of care in the treatment of venous leg ulcers

Phase 3 study evaluating efficacy and safety of DSC127 compared with vehicle and with standard-of-care in diabetic foot ulcers (Stride 2)

Open-label study in diabetic foot ulcers (DFU), to evaluate safety of 0.03% DSC127 topical gel in chronic use (Stride 5)

In-home assessment of a smart foot mat for prevention of diabetic foot ulcers

A prospective, randomized, double-blind multicenter study comparing continuous diffusion of oxygen (CDO) therapy to standard moist wound therapy (MWT) in the treatment of diabetic foot ulcers

The NuTech NuShield and Affinity membrane product evaluation for the treatment of neuropathic diabetic foot ulcers (DFUs)

A randomized, double-blind, multicenter, superiority, placebo-controlled phase 3 study of pexiganan cream 0.8% applied twice daily for 14 days in the treatment of adults with mild infections of diabetic foot ulcers

A randomized, prospective, multi-center feasibility study of APT001 plasma/nitric oxide therapy for the treatment of diabetic foot ulcers

A phase 1b/2a randomized, double-blind, placebo-controlled study to assess the safety, tolerability and efficacy of adjunctive treatment with topically applied MBN-101 in subjects with moderate to severe diabetic foot infection (DFI)

A randomized trial comparing a dual action pneumatic compression system against multi-layer bandaging system: A non-inferiority study

A prospective trial measuring the clinical outcomes for DermACELL AWM in chronic Wagner Grade 3/4 diabetic foot ulcers

A postmarket, prospective evaluation of human placental membrane tissue used as a wound cover for chronic foot ulcers in patients with diabetes

A multicenter prospective, randomized, controlled, comparative parallel study of dehydrated human umbilical cord allograft in the management of diabetic foot ulcers

An evaluation of Biovance, a dehydrated decellularized human amniotic membrane allograft, in diabetic foot ulcers

A pivotal study of the use of plasma/nitric oxide therapy as produced by the APT001 plasma/nitric oxide generator in adult subjects with a diabetic foot ulcer

A prospective, multi-center, randomized controlled trial evaluating the use of Primatrix dermal repair scaffold for the management of diabetic foot ulcers

A phase 2a, randomized, double-blind, multicenter, placebo and active controlled study to assess analgesic efficacy and safety of ASP3662 in subjects with painful diabetic peripheral neuropathy

A randomized, open label controlled trial of Oasis® ultra tri-layer matrix compared to standard care in the healing of diabetic foot ulcers

A phase III, prospective, double-blinded, randomized controlled trial of the micronized dHACM injection as compared to the saline placebo injection in the treatment of plantar fasciitis

A phase III, prospective, double-blinded, randomized controlled trial of the micronized dHACM injection as compared to the saline placebo injection in the treatment of Achilles tendonitis

Dose-response relationship study of S42909 on leg ulcer healing after oral repeated administration in patients with active venous leg ulcer: A 10-week randomized, double-blind, placebo-controlled, prospective, international, multicentre, phase IIa study

A prospective, multi-center, double-blind, randomized, placebo-controlled trial comparing two doses of VF001-DP to placebo as an adjunct to standard care in patients with chronic venous leg ulcers


Presentations

Treatment Methods and Experience Using a Novel Aggregating Powder Dressing, as a Primary Dressing, Over a Single Layer Skin Equivalent. Abstract presented at American College of Foot and Ankle Orthopedics and Medicine Scientific Conference, Orlando, FL, July 2009.

A Randomized, Open Label, Controlled Trial of a Tri‐Layer Extracellular Matrix vs. Standard Care in the Healing of Diabetic Foot Ulcers. Abstract presented at The Symposium on Advanced Wound Care, San Antonio, TX, May 2015.

A Multicenter, Randomized Study to Assess a Sterile, Hydrated Acellular Dermal Matrix Versus Conventional Care Wound Management in Subjects with Venous Stasis Ulcers: An Interim Analysis. Abstract presented at The Symposium on Advanced Wound Care, San Antonio, TX, May 2015.

A Multicenter, Randomized Study to Assess a Sterile, Hydrated Acellular Dermal Matrix versus Conventional Care Wound Management in Subjects with Venous Stasis Ulcers. Abstract presented at The Symposium on Advanced Wound Care, Las Vegas, NV, September 2015.

An Evaluation of Tissue Engineering Approaches for Treatment of Neuropathic Diabetic Foot Ulcers (DFUs) Resistant to Standard of Care (SOC): An Interim Analysis of a Prospective, Randomized Controlled Trial. Abstract presented at The Symposium on Advanced Wound Care, Las Vegas, NV, September 2015.

Healing Rates in a Multicenter Assessment of a Sterile, Room Temperature, Acellular Dermal Matrix vs Conventional Wound Care Management and active Comparator in Treatment of Full Thickness Diabetic Foot Ulcers. Results presented at John A. Boswick Burn Symposium, Maui, HI, February 2016.

Healing Rates in a Multicenter Assessment of a Sterile, Room Temperature, Acellular Dermal Matrix vs Conventional Wound Care Management and active Comparator in Treatment of Full Thickness Diabetic Foot Ulcers. Results presented at Diabetic Limb Salvage Symposium, Georgetown University, Washington, DC, April 2016.

Healing Rates in a Multicenter Assessment of a Sterile, Room Temperature, Acellular Dermal Matrix vs Conventional Wound Care Management and active Comparator in Treatment of Full Thickness Diabetic Foot Ulcers. Results Presented at The Symposium on Advanced Wound Care, Atlanta, GA, April 2016.

Prospective Study Exploring Use of a Sterile, Room Temperature, Acellular Dermal Matrix* to Treat Chronic Wagner Grade 3 & 4 Diabetic Foot Ulcers. Abstract accepted for presentation at The Symposium on Advanced Wound Care, Charlotte, NC, April 2018.

An estimated 550 million people will be diagnosed worldwide by 2030.
Diabetes is a worldwide catastrophe currently affecting approximately 29 million people in the United States.
An individual suffering from diabetes has a 1-in-4 chance of developing a wound over the course of their lifetime.
Greater than 50% of all wounds become infected and approximately 20% of all infected wounds of the lower extremity lead to amputation.
There are currently 6.5 million patients in the United States who require wound care on a regular basis.